United Therapeutics Corp (NASDAQ:UTHR)

CAPS Rating: 4 out of 5

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

Results 1 - 20 of 23 : 1 2 Next »

Recs

0
Member Avatar jsnms (< 20) Submitted: 12/25/2013 12:33:16 AM : Outperform Start Price: $112.56 UTHR Score: +2.30

Recent gap-up with high volume means it will do very well for the next six weeks.

Recs

0
Member Avatar genedom (97.67) Submitted: 9/9/2013 3:50:44 AM : Outperform Start Price: $73.47 UTHR Score: +50.29

Value

Recs

1
Member Avatar healthcarevalue (97.34) Submitted: 7/23/2013 8:02:57 PM : Outperform Start Price: $71.25 UTHR Score: +57.93

UTHR, United Therapeutics Corp, safe debt/equity ratio of 0.24, Return on Invested Capital (ROIC) twelve trailing months of 20.88 and from 2012 of even higher at 23.42, trailing price/earnings ratio at 12.7, reasonably priced and P/E is historically low looking back at valuations over the past nine years. Niche industry focus on chronic illness and life-threatening illness, including pulmonary arterial hypertension, infectious diseases, and lung diseases.

Recs

0
Member Avatar manirg (77.23) Submitted: 6/14/2013 1:12:06 PM : Outperform Start Price: $65.40 UTHR Score: +68.97

a good pick for long run

Recs

0
Member Avatar TerryHoodSr (59.71) Submitted: 5/29/2013 2:41:47 PM : Outperform Start Price: $63.78 UTHR Score: +72.71

3yr rev growth 25%
3yr EPS growth 100%

Recs

0
Member Avatar shaileshnita (71.05) Submitted: 4/22/2013 2:09:44 PM : Outperform Start Price: $61.11 UTHR Score: +76.61

It looks cheap.

Recs

0
Member Avatar picbois (98.57) Submitted: 6/24/2012 6:01:01 PM : Outperform Start Price: $47.71 UTHR Score: +110.87

The figures are amazing, many product protected by patent in disease that are not well served for medication.

Recs

1
Member Avatar Calinvestments (97.32) Submitted: 5/13/2011 1:29:33 PM : Outperform Start Price: $66.81 UTHR Score: +38.17

This is a small/mid cap high growth stock that should outperform the S&P during the bull market.

Recs

0
Member Avatar GTROwner (77.33) Submitted: 4/27/2011 11:32:51 PM : Outperform Start Price: $70.38 UTHR Score: +30.34

Will become the dominant player in the PAH market, strong pipeline in multiple high-profit potential orphan diseases like PAH, ILD, PF, Cancer, Stem Cell, and Virology. 30% annual growth over the last 5+ years.

Recs

0
Member Avatar HardnoseDotCom (73.12) Submitted: 4/25/2011 1:31:30 PM : Outperform Start Price: $69.52 UTHR Score: +30.53

low PEG, strong price uptrend

Recs

0
Member Avatar bez780 (< 20) Submitted: 7/29/2009 10:54:21 AM : Outperform Start Price: $42.96 UTHR Score: +85.33

new drugs

Recs

0
Member Avatar LexTNZorro (77.43) Submitted: 5/4/2009 3:21:31 AM : Outperform Start Price: $33.72 UTHR Score: +142.94

http://seekingalpha.com/article/133869-fda-clinical-trial-updates-watson-pharma-united-therapeutics-auxilium-dendreon?source=feed

Recs

0
Member Avatar fanomatic (< 20) Submitted: 4/20/2009 2:44:19 PM : Underperform Start Price: $28.44 UTHR Score: -198.66

This company is limited with products..... and competition for any existing product(s) will happen soon. Its medical device company (Medicomp) is really a small marginally profitable-if at all -firm run by a youngster who was given the job AND isn't a real board certified/practicing MD.
UTHR stock owners should better prepare to SELL now before and when the stock gets to the mid 40's.

Recs

0
Member Avatar wassercom (89.32) Submitted: 2/22/2009 9:15:12 AM : Outperform Start Price: $34.59 UTHR Score: +101.99

Pipeline looks good.

Recs

0
Member Avatar nysegal (63.96) Submitted: 8/5/2008 2:24:22 AM : Outperform Start Price: $55.78 UTHR Score: +60.77

UTHR is a terrific growth stock; accellerating earnings -- 80% in 08 and 68% in 09; recently reported fantastic earnings above street estimates.

Recs

0
Member Avatar ThxUT (< 20) Submitted: 3/13/2008 12:29:05 PM : Outperform Start Price: $39.76 UTHR Score: +155.00

UT leads the market in pulmonary hypertension with rapid growth and a better product than all the competitors.

Recs

0
Member Avatar SteelBreez99 (89.76) Submitted: 12/11/2007 5:47:28 PM : Outperform Start Price: $54.00 UTHR Score: +93.08

VALUE LINES - TIMELY STOCKS IN TIMELY INDUSTRIES

Recs

0
Member Avatar qasamm (42.59) Submitted: 12/11/2007 1:45:24 PM : Outperform Start Price: $53.69 UTHR Score: +95.75

Amazing leadership- many great suprises found in each annual report (no debt, diversity of pipeline, etc.)

Recs

0
Member Avatar MFClobberMeSilly (70.18) Submitted: 11/9/2007 8:27:36 AM : Outperform Start Price: $50.01 UTHR Score: +106.43

Best biomed

Recs

0
Member Avatar kevrose31 (83.68) Submitted: 11/3/2007 5:52:34 PM : Outperform Start Price: $52.42 UTHR Score: +98.71

Wow.

Results 1 - 20 of 23 : 1 2 Next »

Featured Broker Partners


Advertisement